• <sub id="naktq"><address id="naktq"><nobr id="naktq"></nobr></address></sub>
    <em id="naktq"></em>

      <sub id="naktq"><td id="naktq"><nobr id="naktq"></nobr></td></sub>

      1. <form id="naktq"><th id="naktq"><track id="naktq"></track></th></form>

        <wbr id="naktq"></wbr>

          <big id="naktq"><td id="naktq"></td></big><u id="naktq"><ins id="naktq"></ins></u>
          <form id="naktq"></form>

          A LONG-TERM FOCUS
          ON INNOVATION

          We welcome the opportunity to discuss:

          BUSINESS
          DEVELOPMENT
          COLLABORATIONS

          • In-licensing and / or R&D collaborations
            • Creative collaborations in emerging fields
            • Best-in-class technology platforms and capabilities to enhance the Regeneron antibody pipeline
          • Strategic late-stage development and commercial partnerships with other leading biopharma companies
          • Collaborations that maximize the global potential of our pipeline and ability to deliver new medicines to patients around the globe

          Introduce your assets or discuss
          late-stage partnership

          ACADEMIC &
          RESEARCH
          COLLABORATIONS

          • Non-Clinical Research Collaborations providing investigators from academic and research institutions access to our:

          Learn more

          • Clinical Collaborations / Investigator Initiated Studies (IIS) providing investigators and clinicians access to and / or funding for our:

          Learn more

          OUR BUSINESS DEVELOPMENT STRATEGY

          Our entrepreneurial culture and history as one of the industry’s longest-standing biotech companies fosters a high-science mindset, nimble decision-making and highly collaborative relationships.

          We follow the science, rather than limiting our innovations to any one therapeutic area. We are open to collaboration opportunities with the potential to offer important benefits to patients, representing a true scientific or medical advance. In particular, we consider:

          • Novel platforms that enable next-generation therapeutics
          • Technologies for antibody discovery and development against new / challenging targets
          • New approaches that enhance activity of tumor-directed antibodies
          • Biomarker discovery and validation
          • Drug delivery or formulation technologies that improve the efficacy / safety profile, address a CMC or supply challenge or enhance patient convenience or compliance
          • Studying the potential of combinations pairing our pipeline molecules with other innovative clinical-stage therapeutic candidates
          • Collaborations with leading academic groups to advance our efforts in human genetics, animal model development, target discovery, target validation and antibody discovery

          SOME OF OUR CURRENT COLLABORATORS INCLUDE:


          BAYER logo

          Global ophthalmology
          collaborations

          SANOFI logo

          Antibody and immunotherapy
          collaborations

          Icahn School of Medicine at Mount Sinai logo

          Antibody discovery
          agreement

          Columbia University logo

          Research collaboration on genetic
          basis of familial disease

          TEVA logo

          Global collaboration for
          investigational pain therapeutic

          Intellia Therapeutics logo

          Gene-editing technology
          collaboration

          Adicet Bio logo

          Engineered immune cell
          therapeutics collaboration

          Alnylam Pharmaceuticals logo

          RNA interference (RNAi)
          therapeutics collaboration

          caoponrn免费公开视频